Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737173 | 0.99 | ACACB (0.43) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL1106745 | 0.86 | ACACB (0.42) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL1151941 | 0.85 | CYP4F2 (0.35) | CYP4F2CYP4A11ALDH1A1LMNACYP3A4 | |
| SCHEMBL186569 | 0.83 | ACACB (0.69) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL5902987 | 0.82 | ACACB (0.46) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL186576 | 0.82 | FFAR4 (0.40) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL1106802 | 0.82 | ACACB (0.54) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL186855 | 0.82 | ACACB (0.66) | ACACBACACAFFAR4FFAR1 | |
| SCHEMBL10298119 | 0.82 | ACACB (0.43) | ACACBACACACYP4F2CYP4A11FFAR4 | |
| SCHEMBL18633532 | 0.81 | FFAR4 (0.39) | ACACBACACACYP4F2CYP4A11FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309604-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ACACB 204/4885ACACA 158/4885CYP4F2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.